<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        215-212-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SORTIVA H 100/12.5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LOSARTAN POTASSIUM,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        48.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SPIMACO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&ldquo;Sortiva H&rdquo; is a combination of an angiotensin II receptor antagonist (losartan) and a diuretic (hydrochlorothiazide). Angiotensin II is a substance produced in the body which binds to receptors in blood vessels, causing them to tighten. This results in an increase in blood pressure. Losartan prevents the binding of angiotensin II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure. Hydrochlorothiazide works by making the kidneys pass more water and salt. This also helps to reduce blood pressure.</p><p>&ldquo;Sortiva H&rdquo; is indicated for the treatment of essential hypertension (high blood pressure).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take &ldquo;Sortiva&nbsp;H&rdquo;&nbsp;&nbsp;</strong></p><ul><li><p>If you are allergic (hypersensitive) to losartan, hydrochlorothiazide or to any of the other ingredients in this medicine&nbsp;(listed in section 6).&nbsp;</p></li><li><p>If you are allergic (hypersensitive) to other sulfonamide-derived substances (e. g. other thiazides, some antibacterial drugs such as co-trimoxazole, ask your doctor if you are not sure).&nbsp;&nbsp;</p></li><li><p>If you are more than 3 months pregnant.&nbsp;(2nd and 3rd trimester of pregnancy)&nbsp;(It is also better to avoid &ldquo;Sortiva&nbsp;H&rdquo; in early pregnancy - see Pregnancy).&nbsp;&nbsp;</p></li><li><p>If you have severely impaired liver function.&nbsp;</p></li></ul><ul><li><p>If you have severely impaired kidney function or your kidneys are not producing any urine.&nbsp;&nbsp;</p></li><li><p>If you have low potassium, low sodium or high calcium levels which cannot be corrected by treatment.&nbsp;&nbsp;</p></li><li><p>If you are suffering from gout.&nbsp;&nbsp;</p></li><li><p>If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing&nbsp;aliskiren.&nbsp;&nbsp;</p></li></ul><p><strong>Take special care with &ldquo;Sortiva&nbsp;H&rdquo;&nbsp;&nbsp;</strong></p><p>You must tell your doctor if you think you are (or<u> might become</u>) pregnant. &ldquo;Sortiva&nbsp;H&rdquo; is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).&nbsp;&nbsp;</p><p>It is important to tell your doctor before taking &ldquo;Sortiva&nbsp;H&rdquo;:&nbsp;&nbsp;</p><ul><li><p>If you have previously suffered from swelling of the face, lips, throat or tongue.&nbsp;</p></li><li><p>If you take diuretics (water pills).&nbsp;&nbsp;</p></li><li><p>If you are on a salt-restricted diet.&nbsp;&nbsp;</p></li><li><p>If you have or have had severe vomiting and/or&nbsp;diarrhoea.&nbsp;&nbsp;</p></li></ul><ul><li><p>If you have heart failure.&nbsp;</p></li><li><p>If your liver function is impaired (see section 2 &ldquo;Do not take &ldquo;Sortiva&nbsp;H&rdquo;).&nbsp;&nbsp;</p></li><li><p>If you have narrow arteries to your kidneys (renal artery stenosis) or only have one functioning kidney, or you have recently had a kidney transplant.&nbsp;&nbsp;</p></li><li><p>If you have narrowing of the arteries (atherosclerosis), angina pectoris (chest pain due to poor heart function).&nbsp;&nbsp;</p></li><li><p>If you have &lsquo;aortic or mitral valve stenosis&rsquo; (narrowing of the valves of the heart) or &lsquo;hypertrophic cardiomyopathy&rsquo; (a disease causing thickening of heart muscle).&nbsp;&nbsp;</p></li></ul><ul><li><p>If you are diabetic.&nbsp;&nbsp;</p></li><li><p>If you have had gout.&nbsp;&nbsp;</p></li><li><p>If you have or have had an allergic condition, asthma or a condition that causes joint pain, skin rashes and fever (systemic lupus&nbsp;erythematodus).&nbsp;&nbsp;</p></li><li><p>If you have high calcium or low potassium levels or you are on a low potassium diet.&nbsp;&nbsp;</p></li><li><p>If you need to have an&nbsp;anaesthetic&nbsp;(even at the dentist) or before surgery, or if you are going to have tests to check your parathyroid function, you must tell the&nbsp;doctor or medical staff that you are taking losartan potassium and hydrochlorothiazide tablets.&nbsp;&nbsp;</p></li></ul><ul><li><p>If you suffer from primary hyperaldosteronism (a syndrome associated with increased secretion of the hormone aldosterone by the adrenal gland, caused by an abnormality within the gland).&nbsp;&nbsp;</p></li><li><p>If you are taking any of the following medicines used to treat high blood pressure:</p></li></ul><p>- An ACE-inhibitor (for example&nbsp;enalapril,&nbsp;lisinopril,&nbsp;ramipril), in particular if you have diabetes-related kidney problems.</p><p>-&nbsp; Aliskiren.&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.&nbsp;</p><p>See also information under the heading <strong>&ldquo;Do not take&nbsp;Sortiva&nbsp;H&rdquo;.&nbsp;</strong></p><p><strong>Taking other medicines&nbsp;&nbsp;</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;</p><p>Diuretic agents such as the hydrochlorothiazide contained in &ldquo;Sortiva&nbsp;H&rdquo; may interact with other medicines.&nbsp;&nbsp;</p><p>Preparations containing lithium should not be taken with &ldquo;Sortiva&nbsp;H&rdquo; without close supervision by your doctor.&nbsp;&nbsp;</p><p>Special precautionary measures (e.g. blood tests) may be appropriate if you take potassium supplements, potassium-containing salt substitutes or potassium-sparing medicines, other diuretics (&ldquo;water tablets&rdquo;), some laxatives, medicines for the treatment of gout, medicines to control heart rhythm or for diabetes (oral agents or insulins).&nbsp;&nbsp;</p><p>It is also important for your doctor to know if you are taking&nbsp;&nbsp;</p><ul><li><p>Other medicines to reduce your blood pressure.&nbsp;</p></li><li><p>Steroids.&nbsp;</p></li><li><p>Medicines to treat cancer.&nbsp;</p></li></ul><ul><li><p>Pain killers.&nbsp;&nbsp;</p></li><li><p>Drugs for treatment of fungal infections.&nbsp;</p></li><li><p>Arthritis medicines.&nbsp;</p></li><li><p>Resins used for high cholesterol, such as cholestyramine.&nbsp;</p></li><li><p>Medicines which relax your muscles.&nbsp;&nbsp;</p></li></ul><ul><li><p>Sleeping tablets.&nbsp;&nbsp;</p></li><li><p>Opioid medicines such as morphine.&nbsp;</p></li><li><p>&lsquo;Pressor amines&rsquo; such as adrenaline or other drugs from the same group.&nbsp;</p></li><li><p>Oral agents for diabetes or insulins.&nbsp;&nbsp;</p></li><li><p>Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or&nbsp;aliskiren&nbsp;is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function, and electrolytes in patients on&nbsp;Sortiva&nbsp;H and other agents that affect the RAS.&nbsp;</p></li></ul><ul><li><p>Do not co-administer&nbsp;aliskiren&nbsp;with&nbsp;Sortiva&nbsp;H in patients with diabetes. Avoid use of&nbsp;aliskiren&nbsp;with&nbsp;Sortiva&nbsp;H in patients with renal impairment (GFR &lt;60 ml/min).&nbsp;</p></li><li><p>ACE (angiotensin-converting enzyme) inhibitors (for the treatment of blood pressure, certain heart conditions, kidney disease in patients with diabetes)- Concomitant treatment should be limited to individually defined cases with close monitoring of renal function.&nbsp;</p></li></ul><p>Your doctor may need to change your dose and/or to take other precautions:&nbsp;</p><p>-&nbsp; If you are taking an ACE-inhibitor or&nbsp;aliskiren&nbsp;(see also information under the heading&nbsp;&quot;<strong>Take special care with &ldquo;Sortiva&nbsp;H&rdquo;&nbsp;</strong>&quot;.&nbsp;&nbsp;</p><p>Please also inform your doctor if you are taking &ldquo;Sortiva&nbsp;H&rdquo; and you will be undergoing a radiographic procedure and will be given iodine contrast media.&nbsp;</p><p>&nbsp;</p><p><strong>Taking &ldquo;Sortiva&nbsp;H&rdquo; with food and drink&nbsp;&nbsp;</strong></p><p>You are advised not to drink alcohol whilst taking these tablets: alcohol and &ldquo;Sortiva&nbsp;H&rdquo; tablets may increase each other&rsquo;s effects.&nbsp;&nbsp;</p><p>Dietary salt in excessive quantities may counteract the effect of &ldquo;Sortiva&nbsp;H&rdquo; tablets.&nbsp;&nbsp;</p><p>&ldquo;Sortiva&nbsp;H&rdquo; tablets may be taken with or without food.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding&nbsp;&nbsp;</strong></p><p><strong>Pregnancy&nbsp;&nbsp;</strong></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking &ldquo;Sortiva H&rdquo; before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of &ldquo;Sortiva H&rdquo;. &ldquo;Sortiva H&rdquo; is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p><strong>Breast-feeding&nbsp;&nbsp;</strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. &ldquo;Sortiva&nbsp;H&rdquo; is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Use in children and adolescents&nbsp;&nbsp;</strong></p><p>There is no experience with the use of &ldquo;Sortiva&nbsp;H&rdquo; in children. Therefore, &ldquo;Sortiva&nbsp;H&rdquo; should not be given to children.&nbsp;&nbsp;</p><p><strong>Use in elderly patients&nbsp;&nbsp;</strong></p><p>&ldquo;Sortiva&nbsp;H&rdquo; works equally well in and is equally well tolerated by most older and younger adult patients. Most older patients require the same dose as younger patients.&nbsp;&nbsp;</p><p><strong>Driving and using machines&nbsp;&nbsp;</strong></p><p>When you begin treatment with this medication, you should not perform tasks which may require special attention (for example, driving an automobile or operating dangerous machinery) until you know how you tolerate your medicine.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take &ldquo;Sortiva&nbsp;H&rdquo; exactly as your doctor has instructed you. Your doctor will decide on the appropriate dose of &ldquo;Sortiva&nbsp;H&rdquo; depending on your condition and whether you are taking other medicines. It is important to continue taking &ldquo;Sortiva&nbsp;H&rdquo; for as long as your doctor prescribes it in order to maintain smooth control of your blood pressure.&nbsp;&nbsp;</p><p><strong>High Blood Pressure&nbsp;&nbsp;</strong></p><p>The usual dose of &ldquo;Sortiva H&rdquo; for most patients with high blood pressure is 1 tablet of &ldquo;Sortiva H&rdquo; 50 mg/12.5 mg per day to control blood pressure over the 24-hour period. This can be increased to 2 tablets once daily of Losartan / Hydrochlorothiazide 50 mg/12.5 mg Film-Coated Tablets or changed to 1 tablet daily of Losartan / Hydrochlorothiazide 100 mg/25 mg Film-Coated Tablets (a stronger strength) per day. The maximum daily dose is 2 tablets per day of Losartan / Hydrochlorothiazide 50 mg/12.5 mg Film-Coated Tablets or 1 tablet daily of Losartan / Hydrochlorothiazide 100 mg/25 mg Film-Coated Tablets.</p><p>I<strong>f you take more &ldquo;Sortiva&nbsp;H&rdquo; than you should&nbsp;&nbsp;</strong></p><p>In case of an overdose, contact your doctor immediately so that medical attention may be given promptly. Overdose can cause a drop in blood pressure, palpitations, slow pulse, changes in blood composition, and dehydration.&nbsp;&nbsp;</p><p><strong>If you forget to take &ldquo;Sortiva&nbsp;H&rdquo;&nbsp;&nbsp;</strong></p><p>Try to take &ldquo;Sortiva&nbsp;H&rdquo; daily as prescribed. However, if you miss a dose, do not take an extra dose. Just resume your usual schedule.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, &ldquo;Sortiva&nbsp;H&rdquo; tablets can cause side effects, although not everybody gets them.&nbsp;&nbsp;</p><p>If you experience the following, stop taking &ldquo;Sortiva&nbsp;H&rdquo; tablets and tell your doctor immediately or go to the casualty department of your nearest hospital:&nbsp;&nbsp;</p><p>A severe allergic reaction (rash, itching, swelling of the face, lips, mouth or throat that may cause difficulty in swallowing or breathing).&nbsp;&nbsp;</p><p>This is a serious but rare side effect, which affects more than 1 out of 10,000 patients but fewer than 1 out of 1,000 patients.&nbsp;&nbsp;</p><p>You may need urgent medical attention or&nbsp;hospitalisation.&nbsp;&nbsp;</p><p>The following side effects have been reported:&nbsp;&nbsp;</p><p>Common<em> (affecting less than one person in 10 but more than one person in 100):&nbsp;&nbsp;</em></p><ul><li><p>Cough, upper airway infection, congestion in the nose, sinusitis, and sinus disorder.&nbsp;&nbsp;</p></li><li><p>Diarrhoea, abdominal pain, nausea, indigestion.&nbsp;&nbsp;</p></li><li><p>Muscle pain or cramps, leg pain, back pain.&nbsp;&nbsp;</p></li><li><p>Insomnia, headache, dizziness.&nbsp;&nbsp;</p></li></ul><ul><li><p>Weakness, tiredness, chest pain.&nbsp;</p></li><li><p>Increased potassium levels (which can cause an abnormal heart rhythm), decreased&nbsp;haemoglobin&nbsp;levels.&nbsp;</p></li><li><p>Changes in kidney function including kidney failure.&nbsp;&nbsp;</p></li><li><p>Too low sugar in the blood (hypoglycaemia).&nbsp;&nbsp;</p></li></ul><p>Uncommon <em>(affecting less than one person in 100 but more than one person in 1,000):&nbsp;&nbsp;</em></p><ul><li><p>Anaemia, red or brownish spots on the skin (sometimes especially on the feet, legs, arms and buttocks, with joint pain, swelling of the hands and feet and stomach pain), bruising, reduction in white blood cells, clotting problems, reduced number of platelets.&nbsp;&nbsp;</p></li><li><p>Loss of appetite, increased uric acid levels or frank gout, increased blood sugar levels, abnormal blood electrolyte levels.&nbsp;&nbsp;</p></li><li><p>Anxiety, nervousness, panic disorder (recurring panic attacks), confusion, depression, abnormal dreams, sleep disorders, sleepiness, memory impairment.&nbsp;&nbsp;</p></li><li><p>Pins and needles or similar sensations, pain in the extremities, trembling, migraine, fainting.&nbsp;&nbsp;</p></li></ul><ul><li><p>Blurred vision, burning or stinging in the eyes, conjunctivitis, worsening eyesight, seeing things in yellow.&nbsp;</p></li><li><p>Ringing, buzzing, roaring or clicking in the ears, vertigo.&nbsp;</p></li><li><p>Low blood pressure, which may be associated with changes in posture (feeling light-headed or weak when you stand up, angina (chest pain), abnormal heartbeat, cerebrovascular accident (TIA, &ldquo;mini-stroke&rdquo;), heart attack, palpitations.&nbsp;&nbsp;</p></li><li><p>Inflammation of blood vessels, which is often associated with a skin rash or bruising.&nbsp;</p></li><li><p>Sore throat, breathlessness, bronchitis, pneumonia, water on the lungs (which causes difficulty breathing), nosebleed, runny nose, congestion.&nbsp;&nbsp;</p></li></ul><ul><li><p>Constipation, obstipation, wind, stomach upsets, stomach spasms, vomiting, dry mouth, inflammation of a salivary gland, toothache.&nbsp;&nbsp;</p></li><li><p>Jaundice (yellowing of the eyes and skin), inflammation of the pancreas.&nbsp;&nbsp;</p></li><li><p>Hives, itching, inflammation of the skin, rash, redness of the skin, sensitivity to light, dry skin, flushing, sweating, hair loss.&nbsp;</p></li><li><p>Pain in the arms, shoulders, hips, knees or other joints, joint swelling, stiffness, muscle weakness.&nbsp;&nbsp;</p></li><li><p>Frequent urination including at night, abnormal kidney function including inflammation of the kidneys, urinary tract infection, sugar in the urine.&nbsp;&nbsp;</p></li></ul><ul><li><p>Decreased sexual appetite, impotence.&nbsp;&nbsp;</p></li><li><p>Swelling of the face,&nbsp;localised&nbsp;swelling (oedema), fever.&nbsp;&nbsp;</p></li></ul><p><u>Rare (more than 1 out of 10,000 patients and less than 1 out of 1,000 patients):&nbsp;&nbsp;</u></p><p>Hepatitis (inflammation of the liver), abnormal liver function tests.&nbsp;&nbsp;</p><p><u>Not known&nbsp;&nbsp;</u></p><ul><li><p>Flu-like symptoms.&nbsp;&nbsp;</p></li><li><p>Unexplained muscle pain with dark (tea-colored) urine (rhabdomyolysis).&nbsp;&nbsp;</p></li><li><p>Low levels of sodium in the blood (hyponatraemia).&nbsp;&nbsp;</p></li></ul><ul><li><p>Generally feeling unwell (malaise).&nbsp;&nbsp;</p></li><li><p>Disturbed taste (dysgeusia).&nbsp;</p></li></ul><p>If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor.&nbsp;&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use &ldquo;Sortiva H&rdquo; after the expiry date which is stated on the container.</p><p>The expiry date refers to the last day of that month.</p><p>Store &ldquo;Sortiva H&rdquo; in the original package in order to protect from light and moisture. Do not store the package above 30oC.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are losartan potassium and hydrochlorothiazide.</p><p>● &ldquo;Sortiva H&rdquo; 100 mg/12.5 mg contains 100 mg of losartan potassium and 12.5 mg of hydrochlorothiazide as the active ingredients.</p><p>● &ldquo;Sortiva H&rdquo; 100 mg/25 mg contains 100 mg Losartan potassium and 25 mg Hydrochlorothiazide as the active ingredient.</p><p>● &ldquo;Sortiva H&rdquo; 50 mg/12.5 mg contains 50 mg Losartan potassium and 12.5 mg Hydrochlorothiazide as the active ingredient.</p><p>&ldquo;Sortiva H&rdquo; 100 mg/12.5 mg, &ldquo;Sortiva H&rdquo; 100 mg/25 mg and &ldquo;Sortiva H&rdquo; 50 mg/12.5 mg contain the following inactive ingredients: Avicel PH 102, croscarmellose Sodium, colloidal silicon dioxide, purified talc, magnesium stearate.</p><p>Film-Coating: Polysorbate, titanium dioxide, purified talc, polyethylene glycol, hydroxypropyl methylcellulose, iron oxide red, ariabel yellow.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sortiva H available as film-coated tablets in blister packs of 30 tablets

Sortiva-H 50/12.5mg Tablets 
Light yellow, round biconvex film-coated tablet engraved with “214” on one side and plain on the other side.

Sortiva-H  100/25mg Tablets
Light pink, round biconvex film-coated tablet engraved with  “203” on one side and plain on the other side.
 
Sortiva-H  100/12.5mg Tablets
A light brown color, round, biconvex, film-coated tablet engraved with crescent sign on one side and plain on the other side. 




            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SPIMACO</p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp; Medical Appliance Corporation.</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2015 
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>سورتيفا&nbsp;H&nbsp;هى أقراص مركبة من مضاد لمستقبل أنجيوتنسين&nbsp;2 (لوسارتان) ومدر للبول (هيدروكلوروثيازايد). أنجيوتنسين&nbsp;2 هى عبارة عن مادة تنتج داخل الجسم وترتبط بمستقبلات بالأوعية الدموية،&nbsp;وتسبب تضيقها. مما يسبب ارتفاع لضغط الدم. لوسارتان يمنع ارتباط مادة أنجيوتنسين&nbsp;2 بتلك المستقبلات،&nbsp;مسببا بذلك ارتخاء الأوعية الدموية والذى ينتج عنه انخفاض لضغط الدم. هيدروكلوروثيازايد يعمل على زيادة مرور الماء والأملاح عبر الكلي. مما يساعد أيضا على تقليل ضغط الدم.&nbsp;</p><p>&nbsp;</p><p>سورتيفا&nbsp;H&nbsp;يستخدم لعلاج فرط ضغط الدم الأساسى (ضغط الدم المرتفع).&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>موانع استعمال &quot;سورتيفا&nbsp;H&quot;:&nbsp;</p><ul><li><p>إذا كنت مصابا بفرط الحساسية لمادة لوسارتان،&nbsp;هيدروكلوروثيازايد أو أى من المكونات الأخرى لهذا الدواء&nbsp;( المذكورة في الفقرة 6).&nbsp;</p></li><li><p>إذا كنت مصابا بفرط الحساسية لمادة أخرى من مشتقات السلفوناميد (مثل مركبات الثيازايد الأخرى،&nbsp;بعض الأدوية المضادة للبكتيريا مثل كوتريموكسازول،&nbsp;إذا كنت غير واثق تحدث إلى طبيبك المعالج).&nbsp;</p></li><li><p>إذا كنت&nbsp;حاملا لفترة تزيد عن ثلاثة أشهر&nbsp;(فى الثلاث شهور الثانية و الثالثة). (من الأفضل أيضا تجنب تناول سورتيفا&nbsp;H&nbsp;خلال الفترة الأولى من الحمل- انظر الحمل).&nbsp;</p></li></ul><ul><li><p>إذا كنت مصابا بقصور حاد بوظائف الكبد.&nbsp;</p></li><li><p>إذا كنت مصابا بقصور حاد بوظائف الكلية أو فى حالة عدم إفراز الكلى للبول.&nbsp;</p></li><li><p>إذا كان لديك انخفاض فى مستويات البوتاسيوم،&nbsp;الصوديوم أو ارتفاع فى مستوى الكالسيوم والتى لا يمكن تصحيحها عن طريق العلاج.&nbsp;</p></li><li><p>إذا كنت تعانى من النقرس.&nbsp;</p></li><li><p>إذا كان لديك مرض السكري أو اختلال في وظائف الكلى وتقوم بتناول دواء يعمل علي خفض ضغط الدم يحتوي على أليسكيرين.&nbsp;</p></li></ul><p>&nbsp;</p><p><strong>الاحتياطات عند استعمال &quot; سورتيفا&nbsp;H&quot;&nbsp;&nbsp;</strong></p><p>يجب عليك إخبار الطبيب المعالج إذا كنت تعتقدين أنك&nbsp;حاملا&nbsp;أو من الممكن أن تصبحى&nbsp;حاملا. لايوصى باستخدام سورتيفا&nbsp;H&nbsp;خلال الفترة الأولى من الحمل،&nbsp;ولا يمكن تناوله إذا كنت&nbsp;حاملا&nbsp;لفترة تزيد عن ثلاثة أشهر،&nbsp;حيث أنه من الممكن أن يسبب ضررا للجنين إذا تم تناوله فى هذه المرحلة (فضلا انظر فقرة الحمل).&nbsp;</p><p>&nbsp;</p><p>من الضرورى مراجعة طبيبك المعالج قبل تناولك &quot; سورتيفا&nbsp;H&quot; فى الحالات الآتية:&nbsp;</p><ul><li><p>إذا كنت تعانى مسبقا من تورم بالوجه،&nbsp;الشفتين،&nbsp;الحلق أو اللسان.&nbsp;</p></li><li><p>إذا كنت تتناول المواد المدرة للبول.&nbsp;</p></li><li><p>إذا كنت تتبع حمية غذائية محدودة الملح.&nbsp;</p></li><li><p>إذا كنت تعانى حاليا أو مسبقا من التقيؤ الحاد و/ أو الإسهال الشديد.&nbsp;</p></li><li><p>إذا كنت مصابا بفشل فى القلب.&nbsp;</p></li></ul><ul><li><p>إذا كنت مصابا بقصور فى وظائف الكبد (انظر القسم 2 &quot; موانع استعمال سورتيفا&nbsp;H&quot;).&nbsp;</p></li><li><p>إذا كنت مصابا بتضيق فى الشرايين الذاهبة إلى الكلي (تضيق الشريان الكلوى) أو لديك فقط كلية وظيفية واحدة،&nbsp;أو أجريت لك مؤخرا عملية غرس للكلية.&nbsp;</p></li><li><p>إذا كنت مصابا بتضيق فى الشرايين (التصلب العصيدى)،&nbsp;الذبحة الصدرية (وهى ألم فى منطقة الصدر نتيجة قصور وظيفى فى القلب).&nbsp;</p></li><li><p>إذا كنت مصابا بتضيق فى صمام الأبهر أو الصمام التاجى (ضيق فى صمامات القلب) أو &quot;اعتلال القلب الضخامى&quot; (وهو مرض يسبب تضخم فى عضلة القلب).&nbsp;</p></li><li><p>إذا كنت مصابا بداء السكرى.&nbsp;</p></li></ul><ul><li><p>إذا كنت مصابا بالنقرس.&nbsp;&nbsp;</p></li><li><p>إذا كنت تعانى حاليا أو مسبقا من الحساسية،&nbsp;الربو أو أى مسبب من مسببات ألم المفاصل،&nbsp;الطفح الجلدى،&nbsp;والحمى (الذئبة الحمامية).&nbsp;</p></li><li><p>إذا كان لديك ارتفاع فى مستوى الكالسيوم أو انخفاض فى مستوى البوتاسيوم أو كنت تتبع حمية غذائية قليلة البوتاسيوم.&nbsp;</p></li></ul><p>إذا كنت تحتاج إلى استخدام مخدر (حتى لو كان للأسنان) أو قبل الجراحة،&nbsp;أو إذا كنت تريد الذهاب لفحص وظيفة الغدة الدرقية،&nbsp;يجب عليك إخبار الطبيب والفريق الطبى بأنك تتناول أقراص لوسارتان بوتاسيوم و هيدروكلوروثيازايد.&nbsp;</p><ul><li><p>&nbsp;إذا كنت تعانى من فرط الألدوستيرون الابتدائى (وهى متلازمة مصحوبة بزيادة إفراز هرمون الألدوستيرون من الغدة الكظرية،&nbsp;تنتج عن خلل بالغدة).&nbsp;</p></li></ul><ul><li dir="rtl"><p>إذا كنت تتناول أي من الأدوية التالية والتي تستخدم لعلاج ارتفاع ضغط الدم:</p></li></ul><p>-&nbsp; مثبطات إنزيم&nbsp;ACE&nbsp;(على سبيل المثال إنالابريل، ليسينوبريل، راميبريل)، ولا سيما إذا كانت لديك مشاكل في الكلى المتصلة بالسكري.&nbsp;</p><p>-&nbsp; أليسكيرين&nbsp;</p><p>قد يتحقق طبيبك من وظيفة الكلى الخاصة بك، وضغط الدم، وكمية الشوارد (مثل البوتاسيوم) في الدم على فترات منتظمة.&nbsp;</p><p>&nbsp;</p><p>انظر أيضا المعلومات تحت عنوان &quot;&nbsp;لا تقم بتناول سورتيفا&nbsp;H&quot;.&nbsp;</p><p>&nbsp;</p><p><strong>فى حال تناول أدوية أخرى&nbsp;</strong></p><p>رجاء أخبر طبيبك المعالج أو الصيدلى الذى تتعامل معه فى حالة تناولك مسبقا أوحديثا لأى أدوية أخرى،&nbsp;بما فيها الأدوية التى تتناولها بدون وصفة طبية.&nbsp;</p><p>المواد المدرة للبول مثل هيدروكلوروثيازايد الموجود فى &quot; سورتيفا&nbsp;H&quot; من الممكن ان يتفاعل مع بعض الادوية الاخرى.&nbsp;</p><p>التحضيرات التى تحتوى على الليثيوم يجب عدم تناولها مع &quot; سورتيفا&nbsp;H&quot; إلا تحت إشراف الطبيب.&nbsp;</p><p>التدابير الوقائية الخاصة (مثل اختبارات الدم) من الممكن ان تكون مناسبة فى حالة تناول المكملات التى تحتوى على البوتاسيوم،&nbsp;بدائل الملح المحتوية على البوتاسيوم أو العقاقير المقتصدة للبوتاسيوم،&nbsp;بعض المواد الاخرى المدرة للبول،&nbsp;بعض الملينات،&nbsp;الادوية المستخدمة لعلاج النقرس،&nbsp;الادوية المنظمة لضربات القلب أو أدوية علاج السكرى (سواء كانت أدوية تعطى عن طريق الفم أو الإنسولينات).&nbsp;</p><p>&nbsp;</p><p>من الضرورى أيضا إخبار طبيبك المعالج فى حالة تناولك للادوية الاتية:&nbsp;</p><ul><li><p>أدوية اخرى لتقليل ضغط الدم لديك.&nbsp;</p></li><li><p>المركبات الشبيهة بالكوليستيرول.&nbsp;</p></li><li><p>عقاقير لعلاج السرطان.&nbsp;</p></li></ul><ul><li><p>المسكنات.&nbsp;</p></li><li><p>أدوية لعلاج العدوى الفطرية.&nbsp;</p></li><li><p>أدوية لعلاج التهاب المفاصل.&nbsp;</p></li><li><p>راتينات تستخدم لارتفاع الكوليستيرول،&nbsp;مثل كوليستيرامين.&nbsp;</p></li><li><p>أدوية تسبب ارتخاء العضلات.&nbsp;</p></li></ul><ul><li><p>المنومات.&nbsp;</p></li><li><p>مشتقات الأفيون مثل المورفين.&nbsp;</p></li><li><p>الأمينات المسببة لارتفاع ضغط الدم مثل الأدرينالين وبعض الأدوية الاخرى من نفس المجموعة.&nbsp;</p></li><li><p>أدوية علاج السكرى سواء كانت أدوية تعطى عن طريق الفم أو الإنسولينات.&nbsp;</p></li><li><p>الانسداد المزدوج لنظام رينين-أنجيوتنسين (RAS) باستخدام حاصرات أنجيوتنسين أو مثبطات إنزيم&nbsp;ACE&nbsp;أو أليسكيرين يكون مصحوبا بزيادة خطورة انخفاض ضغط الدم وارتفاع مستوى البوتاسيوم فى الدم وتغيرات فى وظائف الكلى (بما في ذلك الفشل الكلوي الحاد) مقارنة باستخدام العلاج المنفرد. لذلك ينبغى مراقبة ضغط الدم و وظائف الكلى و الشوارد بصورة دقيقة لدى المرضى الذين يتناولون سورتيفا&nbsp;H&nbsp;و بعض الأدوية الأخرى التى تؤثر على (RAS).&nbsp;</p></li></ul><ul><li><p>لا تتناول أليسكيرين مع لوسارتان إذا كنت مريض بالسكرى.&nbsp;&nbsp;وتجنب تناول أليسكيرين مع سورتيفا&nbsp;H&nbsp;إذا كان لديك خلل فى وظائف الكلى (معدل الترشيح الكبيبى &lt; 60 مل/دقيقة).&nbsp;</p></li><li><p>مثبطات إنزيم (ACE) (الإنزيم المحول للأنجيوتنسين) (لعلاج ضغط الدم، وبعض أمراض القلب، أمراض الكلى في المرضى الذين يعانون من مرض السكري) - العلاج المتزامن ينبغي أن يقتصر على حالات محددة بشكل فردي مع مراقبة دقيقة لوظيفة الكلى.&nbsp;</p></li></ul><p>قد يحتاج طبيبك إلى تغيير الجرعة و / أو اتخاذ الاحتياطات الأخرى:&nbsp;</p><p>إذا كنت تتناول مثبط إنزيم&nbsp;ACE&nbsp;أو أليسكيرين (انظر أيضا المعلومات تحت عنوان الاحتياطات عند استعمال &quot; سورتيفا&nbsp;H&quot;.&nbsp;</p><p>&nbsp;</p><p>فضلا أخبر طبيبك المعالج إذا كنت تتناول أقراص &quot;سورتيفا&nbsp;&nbsp;H&quot; وسوف تقوم بتصوير شعاعى داخلى عن طريق استخدام اليود.&nbsp;</p><p>&nbsp;</p><p><strong>تناول &quot;سورتيفا&nbsp;H&quot; مع الطعام و الشراب:&nbsp;</strong></p><p>ينصح بعدم تناول الكحول فى حالة تناول هذا الدواء: حيث أن الكحول و أقراص سورتيفا&nbsp;H&nbsp;من الممكن ان يزيد كل منهما من تأثير الآخر.&nbsp;</p><p>تناول ملح الطعام&nbsp; بكميات كبيرة ربما يعاكس تأثير أقراص &quot;سورتيفا&nbsp;H&quot;.&nbsp;</p><p>يمكن تناول أقراص &quot;سورتيفا&nbsp;H&quot; مع الطعام أو بدونه&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>الحمل والرضاعة&nbsp;</strong></p><p><strong>الحمل&nbsp;</strong></p><p>يجب عليك إخبار الطبيب المعالج إذا كنت تعتقدين أنك&nbsp;حاملا&nbsp;أو من الممكن أن تصبحى&nbsp;حاملا. سوف ينصح الطبيب بإيقاف تناول أقراص &quot;سورتيفا&nbsp;H&quot; قبل ان تصبحى&nbsp;حاملا&nbsp;أو حالما تعرفين بانك&nbsp;حاملا&nbsp;وسوف ينصح باستخدام دواء آخر بدلا من &quot;سورتيفا&nbsp;H&quot;&nbsp;</p><p>لايوصى باستخدام سورتيفا&nbsp;&nbsp;H&nbsp;خلال الفترة الأولى من الحمل،&nbsp;ولا يمكن تناوله إذا كنت&nbsp;حاملا&nbsp;لفترة تزيد عن ثلاثة أشهر،&nbsp;حيث أنه من الممكن أن يسبب ضررا للجنين إذا تم تناوله بعد الشهر الثالث من الحمل.&nbsp;</p><p><strong>الرضاعة&nbsp;</strong></p><p>يجب عليك إخبار الطبيب المعالج إذا كنت تقومين أو سوف تبدئين بإرضاع طفلك طبيعيا. لايوصى باستخدام سورتيفا&nbsp;H&nbsp;للأمهات المرضعات،&nbsp;وسوف يلجأ الطبيب الى وصف دواء اخر لك إذا كنت ترغبين فى إكمال الارضاع.&nbsp;</p><p>&nbsp;</p><p>ا<strong>لاستخدام في حالة الأطفال و المراهقين&nbsp;</strong></p><p>لا توجد خبرة كافية عن استخدام أقراص &quot;سورتيفا&nbsp;H&quot; للاطفال. لذلك لا ينصح باستخدام أقراص &quot;سورتيفا&nbsp;H&quot; للاطفال.&nbsp;</p><p>&nbsp;</p><p>ا<strong>لاستخدام في حالة كبار السن&nbsp;</strong></p><p>&quot;سورتيفا&nbsp;H&quot; يعمل بشكل فعال ويمكن تحمله بشكل جيد من قبل المرضى كبار السن والبالغين. يتطلب علاج معظم المرضى كبار السن نفس الجرعة الموصوفة لصغار السن.&nbsp;</p><p>&nbsp;</p><p><strong>تأثير &quot;سورتيفا&nbsp;H&quot; على القيادة واستخدام الآلات&nbsp;</strong></p><p>عند تعرضك للعلاج بهذا الدواء يجب عليك عدم القيام بالمهام التى تتطلب انتباه شديد (مثل قيادة المركبات أو تشغيل الآلات الخطيرة) الى ان تعرف مدى تحملك لهذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>قم دائما بتناول &quot;سورتيفا&nbsp;H&quot; كيفما أخبرك طبيبك المعالج بالضبط. سوف يقوم الطبيب بوصف الجرعة المناسبة لك من سورتيفا&nbsp;H&nbsp;اعتمادا على حالتك وعلى تناولك لادوية اخرى. من الضرورى الاستمرار فى تناول سورتيفا&nbsp;H&nbsp;للفترة التى يحددها الطبيب المعالج وذلك للحفاظ على التحكم السلس بضغط الدم.&nbsp;</p><p>&nbsp;</p><p><strong>ضغط الدم المرتفع&nbsp;</strong></p><p>الجرعة المعتادة من سورتيفا&nbsp;H&nbsp;لمعظم مرضى ضغط الدم المرتفع هى قرص واحد يوميا من سورتيفا&nbsp;H&nbsp;50ملجم /12.5&nbsp; ملجم للتحكم فى ضغط الدم على مدار 24 ساعة. من الممكن زيادة الجرعة الى قرصين مرة واحدة يوميا من&nbsp;لوسارتان/ هيدروكلوروثيازايد 50 ملجم/12.5ملجم أقراص مغطاه بطبقة رقيقة أو تغيير الجرعة الى قرص واحد يوميا من لوسارتان/ هيدروكلوروثيازايد 100 ملجم/25 ملجم أقراص مغطاه بطبقة رقيقة (التركيز الاقوى). أقصى جرعة يمكن تناولها يوميا هى قرصين من لوسارتان/ هيدروكلوروثيازايد&nbsp; 50ملجم/12.5 ملجم أقراص مغطاه بطبقة رقيقة أو قرص واحد يوميا من لوسارتان/ هيدروكلوروثيازايد 100 ملجم/25 ملجم أقراص مغطاه بطبقة رقيقة.&nbsp;</p><p>&nbsp;</p><p><strong>الجرعة الزائدة من&quot; سورتيفا&nbsp;H&quot;&nbsp;</strong></p><p>فى حالة تناول جرعة زائدة من&quot; سورتيفا&nbsp;H&quot;،&nbsp;تواصل مع طبيبك المعالج فورا ليتم الانتباه الطبى والتعامل مع حالتك فى الحال. الجرعة الزائدة ممكن ان تتسبب فى هبوط ضغط الدم بشكل كبير،&nbsp;خفقان،&nbsp;بطء فى النبض،&nbsp;تغيرات فى تركيب الدم،&nbsp;والجفاف.&nbsp;</p><p>&nbsp;</p><p><strong>نسيان تناول جرعة &quot; سورتيفا&nbsp;H&quot;&nbsp;</strong></p><p>حاول أن تأخذ &quot; سورتيفا&nbsp;H&quot; يوميا كما هو موصوف لك من قبل الطبيب المعالج. بالرغم من ذلك فى حالة نسيانك للجرعة،&nbsp;لا تقم بتناول جرعة إضافية. فقط استأنف البرنامج العلاجى المعتاد لديك.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو شأن جميع الأدوية يمكن أن يسبب عقار&quot; سورتيفا&nbsp;H&quot; تأثيرات جانبية، ولو أن تلك التأثيرات لا تحدث لكل من يتناول الدواء.&nbsp;</p><p>فى حالة شعورك بأى من هذه الاعراض توقف عن تناول عقار&quot; سورتيفا&nbsp;H&quot; وقم بالتواصل مع طبيبك المعالج فورا أو اذهب إلى قسم الطوارئ فى أقرب مستشفى:&nbsp;</p><p>حساسية مفرطة ( طفح جلدى،&nbsp;حكة،&nbsp;تورم بالوجه،&nbsp;الشفتين،&nbsp;الفم أو الحلق مما قد يسبب صعوبة فى البلع أو التنفس).&nbsp;تلك الأعراض خطيرة ولكنها نادرة الحدوث،&nbsp;قد تصيب أكثر من مريض واحد من كل&nbsp;10,000&nbsp;مريض وأقل من مريض واحد من كل&nbsp;1,000&nbsp;مريض. قد تحتاج فى هذه الحالة إلى تدخل طبى سريع أو الاحتجاز بالمستشفى.&nbsp;</p><p>&nbsp;</p><p>الأعراض الجانبية الآتية قد تم تسجيلها:&nbsp;</p><p>&nbsp;أعراض جانبية شائعة (تصيب أقل من شخص واحد لكل 10 أشخاص لكنها تصيب أكثر من شخص واحد لكل 100 شخص):&nbsp;</p><ul><li><p>السعال،&nbsp;عدوى المجرى الهوائى العلوى،&nbsp;احتقان الأنف،&nbsp;التهاب الجيوب الأنفية،&nbsp;اضطراب الجيوب الأنفية.&nbsp;</p></li><li><p>إسهال،&nbsp;ألم بالبطن،&nbsp;غثيان،&nbsp;عسر هضم.&nbsp;</p></li></ul><ul><li><p>ألم أو تشنج بالعضلات،&nbsp;ألم بالساق،&nbsp;ألم بالظهر.&nbsp;</p></li><li><p>أرق،&nbsp;صداع،&nbsp;دوخة.&nbsp;</p></li><li><p>ضعف،&nbsp;إرهاق،&nbsp;ألم بالصدر.&nbsp;</p></li><li><p>ارتفاع مستوى البوتاسيوم (والذى قد يسبب عدم انتظام فى إيقاع القلب)،&nbsp;نقص مستوى الهيموجلوبين.&nbsp;</p></li><li><p>تغيرات فى وظائف الكلى وتشمل الفشل الكلوى.&nbsp;</p></li></ul><ul><li><p>نقص شديد فى مستوى السكر بالدم (هيبوجلايسيميا).&nbsp;</p></li></ul><p>&nbsp;</p><p>أعراض جانبية غير شائعة (تصيب أقل من شخص واحد لكل 100 شخص لكنها تصيب أكثر من شخص واحد لكل&nbsp;1,000&nbsp;شخص):&nbsp;</p><ul><li><p>فقر الدم، بقع حمراء أو بنية اللون على الجلد (في بعض الأحيان خصوصا في القدمين والساقين والذراعين والأرداف، مع آلام في المفاصل، وتورم في اليدين والقدمين وآلام في المعدة)، وكدمات، ونقص في خلايا الدم البيضاء، ومشاكل تخثر الدم، وخفض عدد الصفائح الدموية&nbsp;</p></li><li><p>فقدان الشهية، وزيادة مستويات حمض اليوريك أو النقرس، وزيادة مستويات السكر في الدم، مستويات غير طبيعية من الشوارد&nbsp;في الدم.&nbsp;</p></li></ul><ul><li><p>القلق، العصبية، الهلع (نوبات هلع متكررة)، والارتباك، والاكتئاب، وأحلام غير طبيعية، واضطرابات النوم، النعاس، ضعف الذاكرة.&nbsp;</p></li><li><p>إحساس شبيه بالوخز بالإبر أو الدبابيس،&nbsp;ألم فى الاطراف،&nbsp;ارتجاف،&nbsp;صداع نصفى،&nbsp;إغماء.&nbsp;</p></li><li><p>عدم وضوح الرؤية، حرق أو لسع في العينين، والتهاب الملتحمة، وتدهور البصر، ورؤية الأشياء باللون الأصفر.&nbsp;</p></li><li><p>رنين، طنين، زمجرة أو نقر فى الأذنين، ودوار.&nbsp;</p></li><li><p>انخفاض ضغط الدم، والتي قد تترافق مع تغيرات في الحالة (الشعور بالطيش أو الضعف عند الوقوف، والذبحة الصدرية (ألم في الصدر)، نبض غير طبيعي بالقلب ، والحوادث الوعائية الدماغية (&quot;سكتة دماغية مصغرة&quot;)، نوبة قلبية، وخفقان.&nbsp;</p></li></ul><ul><li><p>التهاب الأوعية الدموية، والذي كثيرا ما يرتبط مع طفح جلدي أو كدمات&nbsp;</p></li><li><p>التهاب الحلق، وضيق في التنفس والتهاب الشعب الهوائية والالتهاب الرئوي، ماء على الرئتين (الذي يسبب صعوبة في التنفس)، نزيف وسيلان واحتقان الأنف.&nbsp;</p></li><li><p>إمساك، إمساك مستعص،&nbsp;ريح ومتاعب في المعدة، تشنجات في المعدة وتقيؤ وجفاف الفم والتهاب الغدة اللعابية، ووجع الاسنان.&nbsp;</p></li><li><p>اليرقان (اصفرار العينين والجلد)، والتهاب البنكرياس&nbsp;</p></li><li><p>الشرى، الحكة، التهاب الجلد، والطفح الجلدي، احمرار في الجلد، والحساسية للضوء، جفاف الجلد،&nbsp;احمرار الوجه،&nbsp;التعرق،&nbsp;سقوط الشعر.&nbsp;</p></li></ul><ul><li><p>ألم في الذراعين والكتفين والوركين والركبتين أو المفاصل الأخرى، وتورم وتصلب المفاصل، وضعف العضلات&nbsp;</p></li><li><p>كثرة التبول في الليل، خلل فى وظائف الكلى وتشمل التهاب الكلى، وعدوى المسالك البولية، وظهور السكر في البول&nbsp;</p></li><li><p>نقص الرغبة الجنسية،&nbsp;العجز الجنسى.&nbsp;</p></li><li><p>تورم فى الوجه،&nbsp;تورم موضعى (أوديما)،&nbsp;حمى.&nbsp;</p></li></ul><p>&nbsp;</p><p>أعراض جانبية نادرة الحدوث (تصيب أكثر من مريض واحد لكل&nbsp;10,000&nbsp;مريض لكنها تصيب أقل من مريض واحد لكل&nbsp;1,000&nbsp;مريض):&nbsp;</p><ul><li><p>الالتهاب الكبدى (التهاب الكبد)،&nbsp;خلل فى وظائف الكبد&nbsp;</p></li></ul><p>أعراض جانبية غير معلومة&nbsp;</p><ul><li><p>أعراض شبيهة بأعراض الأنفلونزا.&nbsp;</p></li><li><p>ألم غير مبرر بالعضلات مع بول غامق اللون (مثل لون الشاى) (انحلال الربيدات).&nbsp;</p></li></ul><ul><li><p>انخفاض مستويات الصوديوم في الدم (نقص صوديوم الدم).&nbsp;</p></li><li><p>عدم الشعور&nbsp; بالارتياح بشكل عام (التوعك).&nbsp;</p></li><li><p>خلل في الإحساس بالطعم (خلل التذوق).&nbsp;</p></li></ul><p>&nbsp;</p><p>إذا لاحظت أن أيا من هذه الآثار الجانبية أصبح جسيما،&nbsp; أو إذا لاحظت ظهور أى أعراض جانبية لم ترد فى هذه النشرة فضلا يرجى أن تخبر طبيبك المعالج.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ الدواء بعيدا عن متناول ونظر الاطفال.&nbsp;</p><p>لا تستعمل أقراص &quot; سورتيفا&nbsp;H&quot; بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط. تاريخ انتهاء الصلاحية يشير إلى آخر يوم&nbsp; فى الشهر المذكور فى تاريخ&nbsp; انتهاء الصلاحية.&nbsp;</p><p>يحفظ سورتيفا&nbsp;H&nbsp;فى العبوة الأصلية وذلك لحمايته من الضوء والرطوبة. لا تقم بتخزينه فى درجة حرارة أعلى من&nbsp;30 درجة مئوية.&nbsp;</p><p>لا ينبغي أن يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير لحماية البيئة.&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المواد الفعالة هى لوسارتان بوتاسيوم و هيدروكلوروثيازايد.&nbsp;</p><p>● &quot; سورتيفا إتش&quot;100ملجم /12.5 ملجم تحتوى على 100 ملجم لوسارتان بوتاسيوم و 12.5ملجم ھيدروكلوروثيازايد كمواد فعالة .</p><p>● &quot; سورتيفا إتش&quot;50 ملجم /12.5 ملجم تحتوى على 50 ملجم لوسارتان لبوتاسيوم و 12.5 ملجم ھيدروكلوروثيازايد كمواد فعالة .</p><p>● &quot; سورتيفا إتش100ملجم /25 ملجم &quot; تحتوى على 100 ملجم لوسارتان بوتاسيوم و 25 ملجم ھيدروكلوروثيازايد كمواد فعالة .</p><p>تحتوى أقراص سورتيفا H- على المواد الاتية كمواد غير فعالة:</p><p>أفيسيل P H 102 : كروسكار ميللوز صوديوم ثانى ،ثاني&nbsp; أكسد سيليكون غروى ،تالك منقى ، ستارات المغنسيوم .</p><p>الغطاء الرقيق للاقراص ،بوليسوربيت: ثانى أكسيد التيتانيوم ،تالك منقى ، بولى إيثيلين جليكول ، ھيدروكسى بروبيل ،ميثيل سيليولوز , اكسيد حديد أحمر .أريابل أصفر</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>تتوفر أقراص سورتيفا H- فى شكل أقراص مغلفة بطبقة رقيقة وتحتوى العبوة على 30 قرص</p><p><strong>أقراص سورتيفا H- 50/12.5 :</strong>&nbsp;أقراص مستديرة مغلفة بطبقة رقيقة ثنائية التحدب لونھا أصفر فاتح محفور عليھا &quot; 214&quot; على جانب واحد</p><p><strong>أقراص سورتيفا</strong><strong>&nbsp;100/25 H-: </strong>أقراص مستديرة مغلفة بطبقة رقيقة ثنائية التحدب لونھا وردى فاتح محفور عليھا &quot; 203&quot; على جانب واحد</p><p><strong>أقراص سورتيفا 100/12.5 H- : </strong> أقراص مستديرة مغلفة بطبقة رقيقة ثنائية التحدب لونھا بنى فاتح محفور عليھا شكل الهلال على جانب واحد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>إنتاج الدوائية&nbsp;</p><p>مصنع الادوية بالقصيم</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية</p><p>&nbsp;المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2015 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sortiva H
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 100 mg of losartan potassium and 12.5 mg of hydrochlorothiazide 
(HCTZ).
For a full list of excipients see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sortiva H is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on losartan or hydrochlorothiazide alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sortiva H may be administered with other antihypertensive agents.</p><p>Sortiva H tablets should be swallowed with a glass of water.</p><p>Sortiva H may be administered with or without food</p><p>Hypertension</p><p>Losartan and hydrochlorothiazide is not for use as initial therapy, but in patients whose blood pressure is not adequately controlled by losartan potassium or hydrochlorothiazide alone. Dose titration with the individual components (losartan and hydrochlorothiazide) is recommended.</p><p>When clinically appropriate direct change from monotherapy to the fixed combination may be considered in patients whose blood pressure is not adequately controlled. The usual maintenance dose of Sortiva H is one tablet of Sortiva H 50 mg/12.5 mg (losartan 50 mg/HCTZ 12.5 mg) once daily. For patients who do not respond adequately to Sortiva H 50 mg/12.5 mg, the dosage may be increased to one tablet of Sortiva H 100 mg/25 mg (losartan 100 mg/ HCTZ 25 mg) once daily. The maximum dose is one tablet of Sortiva H 100 mg/25 mg once daily. In general, the antihypertensive effect is attained within three to four weeks after initiation of therapy. Sortiva H 100/12.5 (losartan 100 mg/ HCTZ 12.5 mg) is available for those patients titrated to 100 mg of Cozaar who require additional blood pressure control. Use in patients with renal impairment and haemodialysis patients No initial dosage adjustment is necessary in patients with moderate renal impairment (i.e. creatinine clearance 30-50 ml/min).</p><p>Losartan and hydrochlorothiazide tablets are not recommended for haemodialysis patients.</p><p>Losartan/HCTZ tablets must not be used in patients with severe renal impairment (i.e. creatinine clearance &lt;30 ml/min) (see section 4.3). Use in patients with intravascular volume depletion Volume and/or sodium depletion should be corrected prior to administration of losartan/HCTZ tablets</p><p><strong>Use in patients with hepatic impairment</strong></p><p>Losartan/HCTZ is contraindicated in patients with severe hepatic impairment (see section 4.3).</p><p><strong>Use in the elderly </strong></p><p>Dosage adjustment is not usually necessary for the elderly.</p><p><strong>Use in children and adolescents (&lt; 18 years)</strong></p><p>There is no experience in children and adolescents. Therefore, losartan/hydrochlorothiazide should not be administered to children and adolescents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to losartan, sulphonamide-derived substances (as hydrochlorothiazide) or to 
any of the excipients.
• Therapy resistant hypokalaemia or hypercalcaemia.
• Severe hepatic impairment; cholestasis and biliary obstructive disorders.
• Refractory hyponatraemia.
• Symptomatic hyperuricaemia/gout0
• 2nd and 3rd trimester of pregnancy (see section 4.4 and 4.6)
• Severe renal impairment (i.e. creatinine clearance <30 ml/min)
• Anuria
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Losartan</u></p><p><strong>Angiooedema</strong></p><p>Patients with a history of angiooedema (swelling of the face, lips, throat, and/or tongue) should be closely monitored (see section 4.8).</p><p><em>Hypotension and Intravascular volume depletion</em> Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium-depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of Sortiva H tablets (see sections 4.2. and 4.3).</p><p><strong>Electrolyte imbalances</strong></p><p>Electrolyte imbalances are common in patients with renal impairment, with or without diabetes, and should be addressed. Therefore, the plasma concentrations of potassium and creatinine clearance values should be closely monitored; especially patients with heart failure and a creatinine clearance between 30- 50 ml/min should be closely monitored. The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan/hydrochlorothiazide is not recommended (see section 4.5).</p><p><strong>Liver function impairment</strong></p><p>Based on pharmacokinetic data which demonstrate significantly increased plasma concentrations of losartan in cirrhotic patients, Sortiva H should be used with caution in patients with a history of mild to moderate hepatic impairment. There is no therapeutic experience with losartan in patients with severe hepatic impairment. Therefore Sortiva H is contraindicated in patients with severe hepatic impairment (see sections 4.2, 4.3 and 5.2).</p><p><strong>Renal function impairment</strong></p><p>As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function, including renal failure, have been reported (in particular, in patients whose renal function is dependent on the renin-angiotensin-aldosterone system, such as those with severe cardiac insufficiency or pre-existing renal dysfunction). As with other drugs that affect the renin-angiotensin-aldosterone system, increases in blood urea and serum creatinine have also been reported in patients with bilateral renal artery stenosis&nbsp;or stenosis of the artery to a solitary kidney; these changes in renal function may be reversible upon discontinuation of therapy. Losartan should be used with caution in patients with bilateral renal artery stenosis or stenosis of the artery to a solitary kidney</p><p><strong>Renal transplantation</strong></p><p>There is no experience in patients with recent kidney transplantation.</p><p><strong>Primary hyperaldosteronism</strong></p><p>Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting through inhibition of the reninangiotensin system. Therefore, the use of Sortiva H tablets is not recommended.</p><p><em>Coronary heart disease and cerebrovascular disease</em></p><p>As with any antihypertensive agents, excessive blood pressure decrease in patients with ischaemic cardiovascular and cerebrovascular disease could result in a myocardial infarction or stroke.</p><p><strong>Heart failure</strong></p><p>In patients with heart failure, with or without renal impairment, there is - as with other drugs acting on the renin-angiotensin system - a risk of severe arterial hypotension, and (often acute) renal impairment. Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyophathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><strong>Ethnic differences</strong></p><p>As observed for angiotensin converting enzyme inhibitors, losartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.</p><p><strong>Pregnancy</strong></p><p>AIIRAs should not be initiated during pregnancy. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p><u>Hydrochlorothiazide</u></p><p><strong>Hypotension and electrolyte/fluid imbalance</strong></p><p>As with all antihypertensive therapy, symptomatic hypotension may occur in some patients. Patients should be observed for clinical signs of fluid or electrolyte imbalance, e.g., volume depletion, hyponatremia, hypochloremic alkalosis, hypomagnesemia or hypokalemia which may occur during intercurrent diarrhea or vomiting. Periodic determination of serum electrolytes should be performed at appropriate intervals in such patients. Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p><strong>Metabolic and endocrine effects</strong></p><p>Thiazide therapy may impair glucose tolerance. Dosage adjustment of antidiabetic agents, including insulin, may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.&nbsp;</p><p>Thiazides may decrease urinary calcium excretion and may cause intermittent and slight elevation of serum calcium. Marked hypercalcemia may be evidence of hidden hyperparathyroidism.</p><p>Thiazides should be discontinued before carrying out tests for parathyroid function. Increases in cholesterol and triglyceride levels may be associated with thiazide diuretic therapy. Thiazide therapy may precipitate hyperuricemia and/or gout in certain patients. Because losartan decreases uric acid, losartan in combination with hydrochlorothiazide attenuates the diuretic-induced hyperuricemia</p><p><strong>Hepatic impairment </strong></p><p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, as it may cause intrahepatic cholestasis, and since minor alterations of fluid and electrolyte balance may precipitate hepatic coma. Sortiva H is contraindicated for patients with severe hepatic impairment (see section 4.3 and 5.2).</p><p><strong>Other</strong></p><p>In patients receiving thiazides, hypersensitivity reactions may occur with or without a history of allergy or bronchial asthma. Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazides.</p><p><strong>Excipient</strong></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Losartan</strong></p><p>Rifampicin and fluconazole have been reported to reduce levels of active metabolite. The clinical consequences of these interactions have not been evaluated.</p><p>As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium. Co-medication is not advisable.</p><p>As with other medicines which affect the excretion of sodium, lithium excretion may be reduced. Therefore, serum lithium levels should be monitored carefully if lithium salts are to be co-administered with angiotensin II receptor antagonists.</p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs (i.e. selective COX-2 inhibitors, acetylsalicylic acid at anti-inflammatory doses) and non-selective NSAIDs, attenuation of the antihypertensive effect may occur. Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.</p><p>The combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring renal function after initiation of concomitant therapy, and periodically thereafter.</p><p>In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, the co-administration of angiotensin II receptor antagonists may result in a further deterioration of renal function. These effects are usually reversible.</p><p>Clinical trial data have shown dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia, and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4, and 5.1).</p><p>Do not co-administer aliskiren with Sortiva H in patients with diabetes. Avoid use of aliskiren with Sortiva H in patients with renal impairment (GFR &lt;60 ml/min).</p><p>Other substances inducing hypotension like tricyclic antidepressants, antipsychotics, baclofene, amifostine: Concomitant use with these drugs that lower blood pressure, as main or side-effect, may increase the risk of hypotension.</p><p><strong>Hydrochlorothiazide</strong></p><p>When given concurrently, the following drugs may interact with thiazide diuretics:</p><p><strong><em>Alcohol, barbiturates, narcotics or antidepressants</em></strong></p><p>Potentiation of orthostatic hypotension may occur.</p><p><strong><em>Antidiabetic drugs (oral agents and insulin</em></strong><em>)</em></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic drug may be required.</p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><strong><em>Other antihypertensive drugs</em></strong></p><p>Additive effect.</p><p><strong><em>Cholestyramine and colestipol resins</em></strong></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.</p><p><strong><em>Corticosteroids, ACTH</em></strong></p><p>Intensified electrolyte depletion, particularly hypokalemia.</p><p><strong><em>Pressor amines (e.g, adrenaline)</em></strong></p><p>Possible decreased response to pressor amines but not sufficient to preclude their use.</p><p><strong><em>Skeletal muscle relaxants, nondepolarizing (e.g, tubocurarine)</em></strong></p><p>Possible increased responsiveness to the muscle relaxant.</p><p><strong><em>Lithium</em></strong></p><p>Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity; concomitant use is not recommended.</p><p><em>Medicinal products used in the treatment of gout (probenecid, sulfinpyrazone and allopurinol)</em></p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><strong><em>Anticholinergic agents (e.g. atropine, biperiden)</em></strong></p><p>Increase of the bioavailability to thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><strong><em>Cytotoxic agents (e.g. cyclophosphamide, methotrexate)</em></strong></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><strong><em>Salicylates</em></strong></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><strong><em>Methyldopa</em></strong></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><strong><em>Cyclosporin</em></strong></p><p>Concomitant treatment with cyclosporin may increase the risk of hyperuricaemia and gout-type complications.</p><p><strong><em>Digitalis glycosides</em></strong></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p>Medicinal products affected by serum potassium disturbances</p><p>Periodic monitoring of serum potassium and ECG is recommended when losartan/hydrochlorothiazide is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>&bull; Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).</p><p>&bull; Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>&bull; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).</p><p>&bull; Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, terfenadine, vincamine IV).</p><p><strong><em>Calcium salts</em></strong></p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored and calcium dosage should be adjusted accordingly.</p><p><strong><em>Laboratory Test Interactions</em></strong></p><p>Because of their effects on calcium metabolism, thiazides may interfere with tests for parathyroid function (see section 4.4).</p><p><strong><em>Carbamazepine</em></strong></p><p>Risk of symptomatic hyponatremia. Clinical and biological monitoring is required.</p><p>Iodine Contrast Media</p><p>In case of diuretic-induced dehydration, there is an increased risk of acute renal failure, especially with high doses of the iodine product.</p><p>Patients should be rehydrated before the administration.</p><p>Amphotericin B (parenteral), corticosteroids, ACTH, stimulant laxatives, or glycyrrhizin (found in liquorice).</p><p>Hydrochlorothiazide may intensify electrolyte imbalance, particularly hypokalaemia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of AIIRAs is contraindicated during the 2nd and 3rd trimester of pregnancy (see section 4.3 and 4.4). Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor Inhibitors (AIIRAs), similar risks may exist for this class of drugs.</p><p>Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately and, if appropriate, alternative therapy should be started. Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see section 5.3). Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended. Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3 and 4.4).</p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, its use during second and third trimesters may compromise foetoplacental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women, except in rare situations where no other alternative treatment could be used.</p><p><strong>Lactation</strong></p><p>Because no information is available regarding the use of Sortiva H during breastfeeding Sortiva H is not recommended and alternative treatments with better established safety profiles during breastfeeding are preferable, especially while nursing a newborn or preterm infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the reactions on the ability to drive and use machines have been performed. However, when driving vehicles or operating machinery it must be borne in mind that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy, in particular during initiation of treatment or when the dose is increased.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions below are classified where appropriate by system organ class and frequency according to the following convention:</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Very common:</p><p>Common:</p><p>Uncommon:</p><p>Rare:</p><p>Very rare:</p><p>Not known:</p></td><td style="vertical-align:top"><p>&ge; 1/10</p><p>&ge; 1/100, &lt;&nbsp;&nbsp;1/10</p><p>&ge; 1/1,000, &le; 1/100</p><p>&ge; 1/10,000, &le; 1/1,000</p><p>&le; &nbsp;1/10,000</p><p>cannot be estimated from the available data</p></td></tr></tbody></table><p>In clinical trials with losartan potassium salt and hydrochlorothiazide, no adverse reactions peculiar to this combination of substances were observed. The adverse reactions were restricted to those which were formerly observed with losartan potassium salt and/or hydrochlorothiazide.</p><p>In controlled clinical trials for essential hypertension, dizziness was the only adverse reaction reported as substance-related that occurred with an incidence greater than placebo in 1% or more of patients treated with losartan and hydrochlorothiazide.</p><p>Next to these effects, there are further adverse reactions reported after the introduction of the product to the market as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Hyperkalaemia, elevation of ALT</p></td><td style="vertical-align:top"><p>rare</p></td></tr></tbody></table><p>The adverse reactions that have been seen with one of the individual components and may be potential adverse reactions with losartan potassium/hydrocholorthiazide are the following:</p><p><u>Losartan</u>:</p><p>The following adverse reactions have been reported for losartan in clinical studies and in post-marketing experience:</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>anaemia, Henoch-Sch&ouml;nlein purpura, ecchymosis, haemolysis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>thrombocytopenia</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>hypotension, orthostatic hypotension, sternalgia, angina pectoris, grade II-AV block, cerebrovascular event, myocardial infarction, palpitation, arrhythmias (atrial fibrillations, sinus bradycardia, tachycardia, ventricular tachycardia, ventricular fibrillation)</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>vertigo, tinnitus</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>blurred vision, burning/stinging in the eye, conjunctivitis, decrease in visual acuity</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>abdominal pain, nausea, diarrhea, dyspepsia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>constipation, dental pain, dry mouth, flatulence, gastritis, vomiting, obstipation</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>pancreatitis</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>asthenia, fatigue, chest pain</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>facial oedema, oedema, fever</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>flu-like symptoms, malaise</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>liver function abnormalities</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>hypersensitivity: anaphylactic reactions, angiooedema including swelling of the larynx and glottis causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue; in some of these patients angiooedema had been reported in the past in connection with the administration of other medicines, including ACE inhibitors;</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>anorexia, gout</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>muscle cramp, back pain, leg pain, myalgia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>arm pain, joint swelling, knee pain, musculoskeletal pain, shoulder pain, stiffness, arthralgia, arthritis, coxalgia, fibromyalgia, muscle weakness</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>rhabdomyolysis</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>headache, dizziness</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>nervousness, paraesthesia, peripheral neuropathy, tremor, migraine, syncope</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>insomnia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>anxiety, anxiety disorder, panic disorder, confusion, depression, abnormal dreams, sleep disorder, somnolence, memory impairment</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>renal impairment, renal failure</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>nocturia, urinary frequency, urinary tract infection</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>decreased libido, erectile dysfunction/impotence</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>cough, upper respiratory infection, nasal congestion, sinusitis, sinus disorder</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>pharyngeal discomfort, pharyngitis, laryngitis, dyspnoea, bronchitis, epistaxis, rhinitis, respiratory congestion</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>alopecia, dermatitis, dry skin, erythema, flushing, photosensitivity, pruritus, rash, urticaria, sweating</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="1" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>vasculitis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>hyperkalaemia, mild reduction of haematocrit and haemoglobin, hypoglycaemia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>mild increase in urea and creatinine serum levels</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>increase in hepatic enzymes and bilirubin</p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>hyponatraemia</p></td><td style="vertical-align:top"><p>non known</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp; <u>Hydrochlorothiazide</u>:</p><table border="1" cellspacing="0" cellpadding="0" style="width:626px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Agranulocytosis, aplastic anaemia, haemolytic anaemia, leukopenia, purpura, thrombocytopenia</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia, hyperglycaemia, hyperuricaemia, hypokalaemia, hyponatraemia</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Cephalalgia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Transient blurred vision, xanthopsia</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Necrotizing angiitis (vasculitis, cutaneous vasculitis)</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Respiratory distress including pneumonitis and pulmonary oedema</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Sialoadenitis, spasms, stomach irritation, nausea, vomiting, diarrhoea, constipation</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Icterus (intrahepatic cholestatis), pancreatitis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td rowspan="1" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Photosensitivity, urticaria, toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Glycosuria, interstitial nephritis, renal dysfunction, renal failure</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fever, dizziness</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with Cozaar Comp.</p><p>Treatment is symptomatic and supportive.</p><p>Therapy with Sortiva H should be discontinued and the patient observed closely. Suggested measures include induction of emesis if ingestion is recent and correction of dehydration, electrolyte imbalance, hepatic coma and hypotension by established procedures.</p><p>Losartan</p><p>Limited data are available in regard to overdose in humans. The most likely manifestation of overdose would be hypotension and tachycardia; bradycardia could occur from&nbsp;parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor the active metabolite can be removed by hemodialysis.</p><p>Hydrochlorothiazide</p><p>The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia may accentuate cardiac arrhythmias.</p><p>The degree to which hydrochlorothiazide is removed by hemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists and diuretics. ATC code: C09DA01</p><p>Losartan-Hydrochlorothiazide</p><p>The components of Sortiva H have been shown to have an additive effect on blood pressure reduction, reducing blood pressure to a greater degree than either component alone. This effect is thought to be a result of the complimentary actions of both components. Further, as a result of its diuretic effect, hydrochlorothiazide increases plasma renin activity, increases aldosterone secretion, decreases serum potassium, and increases the levels of angiotensin II. Administration of losartan blocks all the physiologically relevant actions of angiotensin II and through inhibition of aldosterone could tend to attenuate the potassium loss associated with the diuretic. Losartan has been shown to have a mild and transient uricosuric effect. Hydrochlorothiazide has been shown to cause modest increases in uric acid; the combination of losartan and hydrochlorothiazide tends to attenuate the diuretic-induced hyperuricemia. The antihypertensive effect of Sortiva H is sustained for a 24-hour period. In clinical studies of at least one year&#39;s duration, the antihypertensive effect was maintained with continued therapy. Despite the significant decrease in blood pressure, administration of Sortiva H had no clinically significant effect on heart rate. In clinical trials, after 12 weeks of therapy with losartan 50 mg/hydrochlorothiazide 12.5 mg, trough sitting diastolic blood pressure was reduced by an average of up to 13.2 mmHg. Sortiva H is effective in reducing blood pressure in males and females, blacks and non-blacks and in younger (&lt;65 years) and older (&ge; 65 years) patients and is effective in all degrees of hypertension.</p><p>Losartan</p><p>Losartan is a synthetically produced oral angiotensin-II receptor (type AT1) antagonist. Angiotensin II, a potent vasoconstrictor, is the primary active hormone of the renin-angiotensin system and an important determinant of the pathophysiology of hypertension. Angiotensin II binds to the AT1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland, kidneys and the heart) and elicits several important biological actions, including vasoconstriction and the release of aldosterone. Angiotensin II also stimulates smooth-muscle cell proliferation.</p><p>Losartan selectively blocks the AT1 receptor. In vitro and in vivo losartan and its pharmacologically active carboxylic acid metabolite E-3174 block all physiologically relevant actions of angiotensin II, regardless of the source or route of its synthesis.</p><p>Losartan does not have an agonist effect nor does it block other hormone receptors or ion channels important in cardiovascular regulation. Furthermore, losartan does not inhibit ACE (kininase II), the enzyme that degrades bradykinin. Consequently, there is thus no increase in bradykinin-mediated undesirable effects.</p><p>During the administration of losartan the removal of the angiotensin II negative feedback on renin secretion leads to increased plasma-renin activity (PRA). Increase in the PRA leads to an increase in angiotensin II in plasma. Despite these increases, antihypertensive activity and suppression of the plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade. After the discontinuation of losartan,PRA and angiotensin II values fell within 3 days to the baseline values.</p><p>Both losartan and its principal active metabolite have a far greater affinity for the AT1 receptor than for the AT2 receptor. The active metabolite is 10- to 40-times more active than losartan on a weight for weight basis.</p><p>In a study specifically designed to assess the incidence of cough in patients treated with losartan as compared to patients treated with ACE inhibitors, the incidence of cough reported by patients receiving losartan or hydrochlorothiazide was similar and was significantly less than in patients treated with an ACE inhibitor. In addition, in an overall analysis of 16 doubleblind clinical trials in 4131 patients, the incidence of spontaneously reported cough in patients treated with losartan was similar (3.1%) to that of patients treated with placebo (2.6%) or hydrochlorothiazide (4.1%), whereas the incidence with ACE inhibitors was 8.8%. In nondiabetic hypertensive patients with proteinuria, the administration of losartan potassium significantly reduces proteinuria, fractional excretion of albumin and IgG. Losartan maintains glomerular filtration rate and reduces filtration fraction. Generally losartan causes a decrease in serum uric acid (usually &lt;0.4 mg/dL) which was persistent in chronic therapy. Losartan has no effect on autonomic reflexes and no sustained effect on plasma norepinephrine. In patients with left ventricular failure, 25 mg and 50 mg doses of losartan produced positive hemodynamic and neurohormonal effects characterized by an increase in cardiac index and decreases in pulmonary capillary wedge pressure, systemic vascular resistance, mean systemic arterial pressure and heart rate and a reduction in circulating levels of aldosterone and norepinephrine, respectively. The occurrence of hypotension was dose related in these heart failure patients.</p><p>Hypertension Studies</p><p>In controlled clinical studies, once-daily administration of losartan to patients with mild to moderate essential hypertension produced statistically significant reductions in systolic and diastolic blood pressure. Measurement of blood pressure 24 hours post-dose relative to 5-6 hours post-dose demonstrated blood pressure reduction over 24 hours; the natural diurnal rhythm was retained. Blood pressure reduction at the end of the dosing interval was 70 - 80 % of the effect seen 5-6 hours post-dose. Discontinuation of losartan in hypertensive patients did not result in an abrupt rise in blood pressure (rebound). Despite the marked decrease in blood pressure, losartan had no clinically significant effect on heart rate. Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients</p><p>&nbsp;</p><p>LIFE Study</p><p>The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG-documented left ventricular hypertrophy. Patients were randomised to once daily losartan 50 mg or once daily atenolol 50 mg. If goal blood pressure (&lt;140/90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of losartan or atenolol was then increased to 100 mg once daily. Other antihypertensives, with the exception of ACE inhibitors, angiotensin II antagonists or beta-blockers were added if necessary to reach the goal blood pressure. The mean length of follow up was 4.8 years. The primary endpoint was the composite of cardiovascular morbidity and mortality as measured by a reduction in the combined incidence of cardiovascular death, stroke and myocardial infarction. Blood pressure was significantly lowered to similar levels in the two groups. Treatment with losartan resulted in a 13.0% risk reduction (p=0.021, 95 % confidence interval 0.77-0.98) compared with atenolol for patients reaching the primary composite endpoint. This was mainly attributable to a reduction of the incidence of stroke. Treatment with losartan reduced the risk of stroke by 25% relative to atenolol (p=0.001 95% confidence interval 0.63-0.89). The rates of cardiovascular death and myocardial infarction were not significantly different between the treatment groups.</p><p>Hydrochlorothiazide</p><p>Hydrochlorothiazide is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma rennin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore co-administration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. After oral use, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours the antihypertensive effect persists for up to 24 hours.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p><em>Losartan</em></p><p>Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites. The systemic bioavailability of losartan tablets is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. There was no clinically significant effect on the plasma concentration profile of losartan when the drug was administered with a standardized meal.</p><p>Distribution</p><p><em>Losartan</em></p><p>Both losartan and its active metabolite are &ge;99% bound to plasma proteins, primarily albumin. The volume of distribution of losartan is 34 liters. Studies in rats indicate that losartan crosses the blood-brain barrier poorly, if at all.</p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.</p><p>Biotransformation</p><p><em>Losartan</em></p><p>About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite. Following oral and intravenous administration of 14C-labelled losartan potassium, circulating plasma radioactivity primarily is attributed to losartan and its active metabolite. Minimal conversion of losartan to its active metabolite was seen in about one percent of individuals studied. In addition to the active metabolite, inactive metabolites are formed, including two major metabolites formed by hydroxylation of the butyl side chain and a minor metabolite, an N-2 tetrazole glucuronide.</p><p>Elimination</p><p><em>Losartan</em></p><p>Plasma clearance of losartan and its active metabolite is about 600 ml/min and 50 ml/min, respectively. Renal clearance of losartan and its active metabolite is about 74 ml/min and 26 ml/min, respectively. When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite. The pharmacokinetics of losartan and its active metabolite are linear with oral losartan potassium doses up to 200 mg. Following oral administration, plasma concentrations of losartan and its active metabolite decline polyexponentially with a terminal half-life of about 2 hours and 6-9 hours, respectively. During once-daily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma. Both biliary and urinary excretion contribute to the elimination of losartan and its metabolites. Following an oral dose of 14C-labelled losartan in man, about 35% of radioactivity is recovered in the urine and 58% in the faeces.</p><p>&nbsp;</p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is eliminated unchanged within 24 hours.</p><p>Characteristics in Patients</p><p><em>Losartan-Hydrochlorothiazide</em></p><p>The plasma concentrations of losartan and its active metabolite and the absorption of hydrochlorothiazide in elderly hypertensives are not significantly different from those in young hypertensives.</p><p><em>Losartan</em></p><p>Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-fold and 1.7- fold greater than those seen in young male volunteers. Pharmacokinetic studies showed that the AUC of losartan in Japanese and non-Japanese healthy male subjects is not different. However, the AUC of the carboxylic acid metabolite (E-3174) appears to be different between the two groups, with an approximately 1.5 fold higher exposure in Japanese subjects than in non-Japanese subjects. The clinical significance of these results is not known. Neither losartan nor the active metabolite can be removed by hemodialysis.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of general pharmacology, genotoxicity and carcinogenic potential. The toxic potential of the combination of losartan/hydrochlorothiazide was evaluated in chronic toxicity studies for up to six months duration in rats and dogs after oral administration, and the changes observed in these studies with the combination were mainly produced by the losartan component. The administration of the losartan/hydrochlorothiazide combination induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum, a decrease in heart weight (without a histological correlate) and gastrointestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages). There was no evidence of teratogenicity in rats or rabbits treated with the losartan/hydrochlorothiazide combination. Foetal toxicity in rats, as evidenced by a slight increase in supernumerary ribs in the F1 generation, was observed when females were treated prior to and throughout gestation. As observed in studies with losartan alone, adverse foetal and neonatal reactions, including renal toxicity and foetal death, occurred when pregnant rats were treated with the losartan/hydrochlorothiazide combination during late gestation and/or lactation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline Cellulose (Avicel PH 102)</p><p>Croscarmellose Sodium Type A</p><p>Colloidal Silicon Dioxide</p><p>Purified Talc</p><p>Magnesium Stearate</p><p>Film-Coating:</p><p>Polysorbate 80</p><p>Titanium Dioxide</p><p>Purified Talc</p><p>Polyethylene Glycol MW 6000</p><p>Hydroxypropyl Methylcellulose</p><p>Iron Oxide Red</p><p>Ariabel Yellow</p><p>Purified Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years/24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in original package .</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- White opaque PVC/PDVC reel blister and Aluminum Foil lid</p><p>- Each unit carton contains 30 film-coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Any unused should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>